CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
Rhea-AI Summary
CSL (OTC:CSLLY) and Vifor Fresenius Medical Care Renal Pharma announced that EMA’s CHMP has recommended revoking the EU marketing authorisation for TAVNEOS (avacopan), a treatment for severe, active GPA or MPA ANCA-associated vasculitis, following an Article 20 non-pharmacovigilance review of Phase 3 ADVOCATE trial data handling.
The opinion goes to the European Commission, whose final decision is pending. If confirmed, TAVNEOS will no longer be authorised in the EU, no new patients in the EU/EEA will start treatment, and current patients are advised to consult their physicians.
Positive
- None.
Negative
- CHMP recommends revoking TAVNEOS EU marketing authorisation
- No new TAVNEOS patients in EU and EEA
- Potential loss of EU market for TAVNEOS pending EC decision
News Market Reaction – CSLLY
In the Jun 26 session, CSLLY declined 2.30%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Recommendation follows an Article 20 non-pharmacovigilance procedure
- Patients currently on TAVNEOS treatment should consult their treating physician
ST. GALLEN,
The CHMP opinion has been provided to the European Commission (EC), and a final decision by the EC is expected shortly. If this recommendation is confirmed by the European Commission, TAVNEOS will no longer be authorised in the EU.
The recommendation to revoke the marketing authorisation is based on a review of TAVNEOS under an Article 20 non-pharmacovigilance procedure that was initiated due to concerns related to data handling in the pivotal Phase 3 ADVOCATE trial. TAVNEOS was developed by ChemoCentryx and is commercialised outside the US and in selected countries by CSL, its affiliates and partners pursuant to a collaboration and license agreement between Vifor Fresenius Medical Care Renal Pharma Ltd. and ChemoCentryx. Amgen acquired ChemoCentryx in 2022.
"While we are disappointed in the outcome of the Article 20 procedure, we will respect the outcome of the regulatory process and are committed to implementing it in full. We recognise this is a difficult moment for the community, as TAVNEOS has played an important role for patients living with ANCA-associated vasculitis, a life-threatening disease with limited treatment options. VFMCRP and CSL remain focused on bringing innovative treatment options to patients living with rare diseases," said Dr. Bill Mezzanotte, Head of Research and Development, CSL. "Patient care remains our highest priority, and we are working closely with regulatory authorities, healthcare professionals and patient organisations to ensure a compliant and appropriate treatment transition, along with ongoing support for patients."
No new patients will be treated with TAVNEOS in the EU and the European Economic Area. Patients currently on TAVNEOS are advised to consult with their physician.
About ANCA-associated vasculitis (GPA/MPA)
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening disease where the body's immune system mistakenly attacks its own blood vessels. This causes inflammation and irreversible organ damage, most frequently to the kidneys, and lungs, and requires treatment to manage the disease. The two main forms are granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Both disease and treatment burden markedly diminish quality of life for affected patients. The unmet medical need remains high as people living with AAV face significant risk of complications, driven both by the disease and treatment-related adverse effects, including from high dose and/or long-term use of glucocorticoids.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen,
About TAVNEOS® (avacopan)
TAVNEOS® (avacopan) is an orally administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1. By blocking the receptor (the C5aR) for the pro-inflammatory complement system fragment, C5a on inflammatory cells such as blood neutrophils, TAVNEOS inhibits the ability of those cells to do damage in response to C5a activation, which is known to be the driver of inflammation. Moreover, the selective inhibition by TAVNEOS of only the C5aR1 leaves other immune system responses functioning normally.
TAVNEOS was developed by ChemoCentryx, the NDA holder for TAVNEOS in the US, which was acquired by Amgen in 2022. TAVNEOS is commercialized outside the US in selected countries by CSL, its affiliates and partners pursuant to a collaboration and license agreement between Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) and ChemoCentryx.
Media Contact
Martin Wans
Mobile: +49 151 20036422
Email: Martin.Wans@cslbehring.com
IR Contact
Jimmy Baker
P. +61 450 909 211
E: jimmy.baker@csl.com.au
View original content to download multimedia:https://www.prnewswire.com/news-releases/chmp-recommends-revoking-marketing-authorisation-for-tavneos-avacopan-in-the-european-union-302811854.html
SOURCE Vifor International AG (CSL Vifor)